Horizon Pharma PLC (HZNP) Expected to Post Quarterly Sales of $333.27 Million

Wall Street analysts expect Horizon Pharma PLC (NASDAQ:HZNP) to post sales of $333.27 million for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Horizon Pharma’s earnings, with the lowest sales estimate coming in at $329.20 million and the highest estimate coming in at $339.44 million. Horizon Pharma reported sales of $274.22 million during the same quarter last year, which indicates a positive year over year growth rate of 21.5%. The firm is scheduled to announce its next earnings results on Wednesday, February 27th.

On average, analysts expect that Horizon Pharma will report full year sales of $1.19 billion for the current year, with estimates ranging from $1.18 billion to $1.19 billion. For the next fiscal year, analysts anticipate that the firm will report sales of $1.26 billion, with estimates ranging from $1.22 billion to $1.31 billion. Zacks Investment Research’s sales averages are an average based on a survey of research firms that follow Horizon Pharma.

Horizon Pharma (NASDAQ:HZNP) last posted its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported $0.65 EPS for the quarter, beating analysts’ consensus estimates of $0.50 by $0.15. The company had revenue of $325.30 million for the quarter, compared to analyst estimates of $311.84 million. Horizon Pharma had a negative net margin of 18.70% and a positive return on equity of 27.14%. Horizon Pharma’s quarterly revenue was up 19.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.26 earnings per share.

HZNP has been the topic of a number of recent research reports. BMO Capital Markets lowered shares of Horizon Pharma from an “outperform” rating to a “market perform” rating and set a $18.00 price objective on the stock. in a research note on Monday, August 6th. Cantor Fitzgerald set a $21.00 price objective on shares of Horizon Pharma and gave the company a “buy” rating in a research note on Wednesday, August 8th. Mizuho restated a “buy” rating and issued a $18.00 price objective on shares of Horizon Pharma in a research note on Wednesday, August 8th. Piper Jaffray Companies restated a “buy” rating and issued a $25.00 price objective on shares of Horizon Pharma in a research note on Thursday, August 9th. Finally, Cowen restated a “buy” rating and issued a $25.00 price objective on shares of Horizon Pharma in a research note on Thursday, August 9th. Six analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. Horizon Pharma currently has an average rating of “Buy” and an average price target of $23.25.

NASDAQ HZNP traded down $0.41 during trading on Friday, reaching $19.98. The company’s stock had a trading volume of 2,042,603 shares, compared to its average volume of 2,258,968. The company has a debt-to-equity ratio of 2.06, a quick ratio of 1.86 and a current ratio of 1.94. The firm has a market cap of $3.42 billion, a PE ratio of 16.93, a P/E/G ratio of 1.35 and a beta of 1.29. Horizon Pharma has a twelve month low of $12.55 and a twelve month high of $23.38.

In other news, Chairman Timothy P. Walbert sold 408,347 shares of the business’s stock in a transaction dated Wednesday, November 14th. The shares were sold at an average price of $21.54, for a total transaction of $8,795,794.38. Following the transaction, the chairman now directly owns 650,404 shares in the company, valued at $14,009,702.16. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 3.90% of the company’s stock.

Several institutional investors have recently modified their holdings of HZNP. First Quadrant L P CA boosted its holdings in Horizon Pharma by 189.1% during the third quarter. First Quadrant L P CA now owns 6,117 shares of the biopharmaceutical company’s stock worth $120,000 after buying an additional 4,001 shares in the last quarter. Quantitative Systematic Strategies LLC purchased a new stake in Horizon Pharma during the second quarter worth about $172,000. Strs Ohio boosted its holdings in Horizon Pharma by 74.2% during the second quarter. Strs Ohio now owns 10,800 shares of the biopharmaceutical company’s stock worth $178,000 after buying an additional 4,600 shares in the last quarter. Ibex Investors LLC purchased a new stake in Horizon Pharma during the third quarter worth about $211,000. Finally, Dynamic Technology Lab Private Ltd purchased a new stake in Horizon Pharma during the third quarter worth about $213,000. Institutional investors and hedge funds own 88.64% of the company’s stock.

About Horizon Pharma

Horizon Pharma Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. The company's marketed medicine portfolio consists of RAVICTI for the treatment of urea cycle disorders; PROCYSBI to treat nephropathic cystinosis; ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; BUPHENYL to treat urea cycle disorders; and QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients.

See Also: What is Considered a Good Return on Equity (ROE)?

Get a free copy of the Zacks research report on Horizon Pharma (HZNP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Horizon Pharma (NASDAQ:HZNP)

Receive News & Ratings for Horizon Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply